Compare STXS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STXS | TVGN |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 21.3M |
| IPO Year | 2004 | 2021 |
| Metric | STXS | TVGN |
|---|---|---|
| Price | $1.32 | $7.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 486.8K | 7.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,346,617.00 | N/A |
| Revenue This Year | $28.22 | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.24 | $0.14 |
| 52 Week High | $3.59 | $12.03 |
| Indicator | STXS | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 68.64 |
| Support Level | $1.30 | $6.41 |
| Resistance Level | $1.51 | $10.59 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 22.45 | 88.89 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.